

Michele Caraglia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8334048/publications.pdf>

Version: 2024-02-01

473
papers

21,525
citations

13865

67
h-index

17105

122
g-index

491
all docs

491
docs citations

491
times ranked

35219
citing authors

#	ARTICLE	IF	CITATIONS
1	Metastatic colorectal cancer and type 2 diabetes: prognostic and genetic interactions. <i>Molecular Oncology</i> , 2022, 16, 319-332.	4.6	13
2	MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 20.	8.6	25
3	Role of miRNA-145, 148, and 185 and Stem Cells in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1626.	4.1	16
4	Clinical and Molecular Characteristics of Rare Malignant Tumors of Colon and Rectum. <i>Biology</i> , 2022, 11, 267.	2.8	8
5	Overview on Molecular Biomarkers for Laryngeal Cancer: Looking for New Answers to an Old Problem. <i>Cancers</i> , 2022, 14, 1716.	3.7	12
6	Initial tumour burden and hidden oligometastatic disease in phase 3 clinical trials. <i>Lancet Oncology</i> , The, 2022, 23, 452-454.	10.7	4
7	Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210968.	3.2	8
8	Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry. <i>Cancers</i> , 2022, 14, 2204.	3.7	12
9	Hybrid Self-Assembling Nanoparticles Encapsulating Zoledronic Acid: A Strategy for Fostering Their Clinical Use. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5138.	4.1	5
10	Polydatin Incorporated in Polycaprolactone Nanofibers Improves Osteogenic Differentiation. <i>Pharmaceuticals</i> , 2022, 15, 727.	3.8	4
11	Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR. <i>Cancers</i> , 2022, 14, 3053.	3.7	7
12	Molecular Characterization of Cancer Associated Fibroblasts in Prostate Cancer. <i>Cancers</i> , 2022, 14, 2943.	3.7	4
13	Tumour Burden Reporting in Phase III Clinical Trials of Metastatic Lung, Breast, and Colorectal Cancers: A Systematic Review. <i>Cancers</i> , 2022, 14, 3262.	3.7	3
14	Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592198922.	3.2	7
15	COVID-19 Outbreak: The North versus South Epidemiologic Italian Paradigm. <i>Journal of Epidemiology and Global Health</i> , 2021, 11, 253.	2.9	4
16	LncRNAs and Immunity: Coding the Immune System with Noncoding Oligonucleotides. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1741.	4.1	32
17	Dysregulation of Principal Cell miRNAs Facilitates Epigenetic Regulation of AQP2 and Results in Nephrogenic Diabetes Insipidus. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1339-1354.	6.1	15
18	KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 632962.	2.8	9

#	ARTICLE	IF	CITATIONS
19	Mood Disorder in Cancer Patients Undergoing Radiotherapy During the COVID-19 Outbreak. <i>Frontiers in Psychology</i> , 2021, 12, 568839.	2.1	6
20	Treatment of Cutaneous Melanoma Harboring SMO p.Gln216Arg Mutation with Imiquimod: An Old Drug with New Results. <i>Journal of Personalized Medicine</i> , 2021, 11, 206.	2.5	2
21	The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3967.	4.1	25
22	Sarcomatoid larynx carcinoma differential clinical evolution, on field statistical considerations. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2021, 42, 102934.	1.3	0
23	Poorly Differentiated Neuroendocrine Larynx Carcinoma: Clinical Features and miRNAs Signature—A New Goal for Early Diagnosis and Therapy?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2019.	2.4	5
24	Mutual Correlation between Non-Coding RNA and S-Adenosylmethionine in Human Cancer: Roles and Therapeutic Opportunities. <i>Cancers</i> , 2021, 13, 3264.	3.7	7
25	Myositis/Myasthenia after Pembrolizumab in a Bladder Cancer Patient with an Autoimmunity-Associated HLA: Immune—Biological Evaluation and Case Report. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6246.	4.1	8
26	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 684110.	2.8	14
27	Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era. <i>Diagnostics</i> , 2021, 11, 1110.	2.6	4
28	Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal. <i>Cancers</i> , 2021, 13, 3284.	3.7	8
29	Polydatin Induces Differentiation and Radiation Sensitivity in Human Osteosarcoma Cells and Parallel Secretion through Lipid Metabolite Secretion. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-11.	4.0	13
30	Efficacy of Unsupervised Self-Collected Mid-Turbinat FLOQSwabs for the Diagnosis of Coronavirus Disease 2019 (COVID-19). <i>Viruses</i> , 2021, 13, 1663.	3.3	3
31	Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study. <i>Cancers</i> , 2021, 13, 4236.	3.7	8
32	Genetic regressive trajectories in colorectal cancer: A new hallmark of oligo-metastatic disease?. <i>Translational Oncology</i> , 2021, 14, 101131.	3.7	14
33	Long non-coding RNAs in cancer stem cells. <i>Translational Oncology</i> , 2021, 14, 101134.	3.7	25
34	Protein Kinase A Detection in Human Urine Samples. <i>Journal of Clinical Medicine</i> , 2021, 10, 4096.	2.4	1
35	S-Adenosylmethionine Inhibits Cell Growth and Migration of Triple Negative Breast Cancer Cells through Upregulating MiRNA-34c and MiRNA-449a. <i>International Journal of Molecular Sciences</i> , 2021, 22, 286.	4.1	11
36	Safety and Efficacy Evaluation In Vivo of a Cationic Nucleolipid Nanosystem for the Nanodelivery of a Ruthenium(III) Complex with Superior Anticancer Bioactivity. <i>Cancers</i> , 2021, 13, 5164.	3.7	14

#	ARTICLE	IF	CITATIONS
37	The Tumor Dynamism Is the Dark Matter of the NGS Galaxy: How to Understand It?. <i>Cancers</i> , 2021, 13, 5476.	3.7	0
38	Abstract PO-052: A pilot study of miRNA expression profile in surgically resected pancreatic ductal adenocarcinoma: Initial report from a bi-institutional cohort. , 2021, , .		0
39	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. <i>Life</i> , 2021, 11, 1235.	2.4	7
40	Mitochondria as playmakers of apoptosis, autophagy and senescence. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 139-153.	5.0	305
41	Definition of miRNA Signatures of Nodal Metastasis in LCa: miR-449a Targets Notch Genes and Suppresses Cell Migration and Invasion. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 20, 711-724.	5.1	24
42	Therapeutic Potential of the Natural Compound S-Adenosylmethionine as a Chemoprotective Synergistic Agent in Breast, and Head and Neck Cancer Treatment: Current Status of Research. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8547.	4.1	15
43	Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA. <i>International Journal of Pharmaceutics</i> , 2020, 588, 119693.	5.2	19
44	Toll-like receptors and COVID-19: a two-faced story with an exciting ending. <i>Future Science OA</i> , 2020, 6, FSO605.	1.9	96
45	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 3073.	3.7	28
46	Î²2-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism. <i>Cell Death and Disease</i> , 2020, 11, 850.	6.3	14
47	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. <i>Cells</i> , 2020, 9, 1964.	4.1	37
48	Extracellular Vesicles: New Endogenous Shuttles for miRNAs in Cancer Diagnosis and Therapy?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6486.	4.1	36
49	Mi-RNA-888-5p Is Involved in S-Adenosylmethionine Antitumor Effects in Laryngeal Squamous Cancer Cells. <i>Cancers</i> , 2020, 12, 3665.	3.7	9
50	Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3693.	4.1	23
51	Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems. <i>Cells</i> , 2020, 9, 1412.	4.1	25
52	Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. , 2020, 8, e000733.		32
53	Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. <i>Frontiers in Oncology</i> , 2020, 10, 1047.	2.8	11
54	Comparative Study of NGS Platform Ion Torrent Personal Genome Machine and Therascreen Rotor-Gene Q for the Detection of Somatic Variants in Cancer. <i>High-Throughput</i> , 2020, 9, 4.	4.4	1

#	ARTICLE	IF	CITATIONS
55	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 275.	6.3	21
56	Anti-Inflammatory Drugs as Anticancer Agents. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2605.	4.1	197
57	Salivary mir-27b Expression in Oral Lichen Planus Patients: A Series of Cases and a Narrative Review of Literature. <i>Current Topics in Medicinal Chemistry</i> , 2020, 19, 2816-2823.	2.1	17
58	Urotensin II receptor expression in patients with ulcerative colitis: a pilot study. <i>Minerva Gastroenterologica E Dietologica</i> , 2020, 66, 23-28.	2.2	3
59	Radiomics predicts survival of patients with advanced non-small cell lung cancer undergoing PD-1 blockade using Nivolumab. <i>Oncology Letters</i> , 2020, 19, 1559-1566.	1.8	46
60	On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1712-1719.	2.8	0
61	On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2020, 9, 1712-1719.	2.8	2
62	Chitosan-coated liposomes loaded with butyric acid demonstrate anticancer and anti-inflammatory activity in human hepatoma HepG2 cells. <i>Oncology Reports</i> , 2019, 41, 1476-1486.	2.6	26
63	A Hydroquinone-Based Derivative Elicits Apoptosis and Autophagy via Activating a ROS-Dependent Unfolded Protein Response in Human Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3836.	4.1	9
64	Efficacy and Safety of Cetuximab plus Radiotherapy in Cisplatin-Unfit Elderly Patients with Advanced Squamous Cell Head and Neck Carcinoma: A Retrospective Study. <i>Chemotherapy</i> , 2019, 64, 48-56.	1.6	5
65	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. <i>CNS Oncology</i> , 2019, 8, CNS32.	3.0	5
66	Long Non-coding RNAs as Important Biomarkers in Laryngeal Cancer and Other Head and Neck Tumours. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3444.	4.1	66
67	Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience. <i>Cancers</i> , 2019, 11, 1504.	3.7	36
68	Clinical and pathological factors predictive of response to neoadjuvant chemotherapy in breast cancer: A single center experience. <i>Oncology Letters</i> , 2019, 18, 3873-3879.	1.8	15
69	Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 253.	8.6	58
70	<p>Dissecting the prevention of estrogen-dependent breast carcinogenesis through Nrf2-dependent and independent mechanisms</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 4937-4953.	2.0	12
71	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. <i>Kidney International</i> , 2019, 96, 555-567.	5.2	47
72	PYK2 promotes HER2-positive breast cancer invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 210.	8.6	20

#	ARTICLE	IF	CITATIONS
73	Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer. <i>Scientific Reports</i> , 2019, 9, 7006.	3.3	46
74	Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2190.	4.1	20
75	miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 391-406.	5.1	30
76	Glucose-6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on breast cancer cells through autophagy perturbation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 160.	8.6	59
77	Cell communication and signaling: how to turn bad language into positive one. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 128.	8.6	21
78	Targeting Autophagy to Overcome Human Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 725.	4.1	83
79	Genomic Profile and BRCA-1 Promoter Methylation Status in BRCA Mutated Ovarian Cancer: New Insights in Predictive Biomarkers of Olaparib Response. <i>Frontiers in Oncology</i> , 2019, 9, 1289.	2.8	10
80	GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up. <i>Frontiers in Oncology</i> , 2019, 9, 1102.	2.8	15
81	Could PD-1/PDL1 immune checkpoints be linked to HLA signature?. <i>Immunotherapy</i> , 2019, 11, 1523-1526.	2.0	15
82	Urotensin-II-Targeted Liposomes as a New Drug Delivery System towards Prostate and Colon Cancer Cells. <i>Journal of Oncology</i> , 2019, 2019, 1-14.	1.3	18
83	AdoMet triggers apoptosis in head and neck squamous cancer by inducing ER stress and potentiates cell sensitivity to cisplatin. <i>Journal of Cellular Physiology</i> , 2019, 234, 13277-13291.	4.1	18
84	Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 105-119.	2.4	107
85	CheckMate 141 trial: all that glitters is not gold. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 169-171.	3.1	11
86	Oxidative stress in chronic lymphocytic leukemia: still a matter of debate. <i>Leukemia and Lymphoma</i> , 2019, 60, 867-875.	1.3	11
87	Vascular endothelial growth factor: An important molecular target of curcumin. <i>Critical Reviews in Food Science and Nutrition</i> , 2019, 59, 299-312.	10.3	51
88	A randomized phase II study comparing cabazitaxel/prednisone to cabazitaxel alone in docetaxel-pretreated men with metastatic castration resistant prostate cancer (mCRPC): The CABACARE trial. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS345-TPS345.	1.6	0
89	Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts. <i>Journal of Cellular Physiology</i> , 2018, 233, 6524-6543.	4.1	106
90	Structural Characterization of Self-Assembling Hybrid Nanoparticles for Bisphosphonate Delivery in Tumors. <i>Molecular Pharmaceutics</i> , 2018, 15, 1258-1265.	4.6	10

#	ARTICLE	IF	CITATIONS
91	Ipilimumab for the treatment of metastatic prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 205-213.	3.1	14
92	Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 1202-1212.	4.1	38
93	The novel role of pyruvium in cancer therapy. <i>Journal of Cellular Physiology</i> , 2018, 233, 2871-2881.	4.1	57
94	S-Adenosylmethionine-mediated apoptosis is potentiated by autophagy inhibition induced by chloroquine in human breast cancer cells. <i>Journal of Cellular Physiology</i> , 2018, 233, 1370-1383.	4.1	34
95	Determination of miRNAs from Cancer Stem Cells Using a Low Density Array Platform. <i>Methods in Molecular Biology</i> , 2018, 1692, 149-156.	0.9	0
96	Dickkopf homolog 3 (<i>DKK3</i>): A candidate for detection and treatment of cancers?. <i>Journal of Cellular Physiology</i> , 2018, 233, 4595-4605.	4.1	23
97	Non-coding RNAs as a new dawn in tumor diagnosis. <i>Seminars in Cell and Developmental Biology</i> , 2018, 78, 37-50.	5.0	38
98	Anti-Cancer and Radio-Sensitizing Effects of Curcumin in Nasopharyngeal Carcinoma. <i>Current Pharmaceutical Design</i> , 2018, 24, 2121-2128.	1.9	33
99	S-Adenosylmethionine regulates apoptosis and autophagy in MCF-7 breast cancer cells through the modulation of specific microRNAs. <i>Cancer Cell International</i> , 2018, 18, 197.	4.1	29
100	Chitosan-Based Polyelectrolyte Complexes for Doxorubicin and Zoledronic Acid Combined Therapy to Overcome Multidrug Resistance. <i>Pharmaceutics</i> , 2018, 10, 180.	4.5	10
101	Mutant p53 blocks SESN1/AMPK/PGC-1 β /UCP2 axis increasing mitochondrial O ₂ production in cancer cells. <i>British Journal of Cancer</i> , 2018, 119, 994-1008.	6.4	40
102	Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine. <i>Oncotarget</i> , 2018, 9, 20539-20554.	1.8	15
103	A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. <i>Cell Death and Disease</i> , 2018, 9, 572.	6.3	138
104	First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2018, 9, 441.	3.5	9
105	The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration. <i>Current Cancer Drug Targets</i> , 2018, 18, 430-441.	1.6	1
106	Melanoma Adjuvant Treatment: Current Insight and Clinical Features. <i>Current Cancer Drug Targets</i> , 2018, 18, 442-456.	1.6	5
107	Optimal Management of Prostate Cancer Based on its Natural Clinical History. <i>Current Cancer Drug Targets</i> , 2018, 18, 457-467.	1.6	10
108	Aryl hydrocarbon receptor, a tumor grade-associated marker of oral cancer, is directly downregulated by polydatin: A pilot study. <i>Oncology Reports</i> , 2018, 40, 1435-1442.	2.6	8

#	ARTICLE	IF	CITATIONS
109	Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs. <i>Breast</i> , 2018, 41, 165-171.	2.2	12
110	Correlation of survival of NSCLC patients given nivolumab with treatment related-eosinophilia, autoimmunity and previous bevacizumab containing regimens.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21008-e21008.	1.6	1
111	Salivary microRNAs as new molecular markers in cleft lip and palate: a new frontier in molecular medicine. <i>Oncotarget</i> , 2018, 9, 18929-18938.	1.8	32
112	Epigenetic Changes Induced by Green Tea Catechins are Associated with Prostate Cancer. <i>Current Molecular Medicine</i> , 2018, 17, 405-420.	1.3	26
113	P2.05-057 Baseline Inflammatory and Immunological Profile Predict the Survival of NSCLC Patients Undergone Palliative Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1067.	1.1	0
114	Measurement of Autophagy by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2017, 1553, 209-216.	0.9	9
115	Antitumor activity of interferon- γ 1a in hormone refractory prostate cancer with neuroendocrine differentiation. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 761-770.	3.3	10
116	Synergistic activity of everolimus and 5-azacytidine in medullary thyroid carcinoma cell lines. <i>Molecular Oncology</i> , 2017, 11, 1007-1022.	4.6	23
117	P2.03a-053 Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab. <i>Journal of Thoracic Oncology</i> , 2017, 12, S921.	1.1	0
118	Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action. <i>Scientific Reports</i> , 2017, 7, 45236.	3.3	46
119	Naturally occurring anti-cancer agents targeting EZH2. <i>Cancer Letters</i> , 2017, 400, 325-335.	7.2	51
120	Impact of curcumin on the regulation of microRNAs in colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2017, 11, 99-101.	3.0	10
121	MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells. <i>Journal of Cellular Physiology</i> , 2017, 232, 1907-1913.	4.1	45
122	UCP2 inhibition induces ROS/Akt/mTOR axis: Role of GAPDH nuclear translocation in genipin/everolimus anticancer synergism. <i>Free Radical Biology and Medicine</i> , 2017, 113, 176-189.	2.9	52
123	FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land. <i>Cancer Letters</i> , 2017, 408, 71-72.	7.2	1
124	Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. <i>Amino Acids</i> , 2017, 49, 517-528.	2.7	9
125	Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment. <i>Scientific Reports</i> , 2017, 7, 17949.	3.3	36
126	Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences. <i>Oncotarget</i> , 2017, 8, 30606-30616.	1.8	40

#	ARTICLE	IF	CITATIONS
127	A miRNA signature suggestive of nodal metastases from laryngeal carcinoma. <i>Acta Otorhinolaryngologica Italica</i> , 2017, 37, 467-474.	1.5	11
128	Micrnas in prostate cancer: an overview. <i>Oncotarget</i> , 2017, 8, 50240-50251.	1.8	113
129	Peptide Functionalization of Silicon for Detection and Classification of Prostatic Cells. <i>Journal of Sensors</i> , 2017, 2017, 1-9.	1.1	4
130	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	2.2	29
131	Stealth liposomes for the delivery of zoledronic acid into tumors enhance the anticancer activity of the drug. <i>Translational Medicine Reports</i> , 2017, 1, .	0.4	0
132	Anti-cancer activity of dose-fractioned mPE +/â” bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients. <i>Journal of Thoracic Disease</i> , 2017, 9, 3123-3131.	1.4	18
133	Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 42926-42938.	1.8	21
134	Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). <i>Oncotarget</i> , 2017, 8, 75904-75913.	1.8	23
135	Testicular cancer from diagnosis to epigenetic factors. <i>Oncotarget</i> , 2017, 8, 104654-104663.	1.8	54
136	Aggressiveness pattern and second primary tumor risk associated with basaloid squamous cell carcinoma of the larynx. <i>Oncotarget</i> , 2017, 8, 95791-95798.	1.8	18
137	Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors. <i>Current Cancer Drug Targets</i> , 2017, 17, 109-121.	1.6	17
138	A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells. <i>In Vivo</i> , 2017, 31, 609-618.	1.3	13
139	Hepatocarcinoma: genetic and epigenetic features. <i>Minerva Gastroenterology</i> , 2017, 64, 14-27.	0.5	15
140	Early detection of laryngeal cancer: prominence of miRNA signature as a new tool for clinicians. <i>Translational Medicine Reports</i> , 2017, 1, .	0.4	3
141	Gene signatures predictive of response to radiotherapy in prostate cancer: a new step towards precision medicine. <i>Translational Cancer Research</i> , 2017, 6, S136-S140.	1.0	0
142	Protective Effect of Tyrosol and S-Adenosylmethionine against Ethanol-Induced Oxidative Stress of Hepg2 Cells Involves Sirtuin 1, P53 and Erk1/2 Signaling. <i>International Journal of Molecular Sciences</i> , 2016, 17, 622.	4.1	30
143	Drug-Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antitlastic Chemotherapy in Cancer Patients with HIV Infection. <i>Frontiers in Pharmacology</i> , 2016, 7, 71.	3.5	31
144	Immunotherapy of colorectal cancer: new perspectives after a long path. <i>Immunotherapy</i> , 2016, 8, 1281-1292.	2.0	19

#	ARTICLE	IF	CITATIONS
145	The 1,4 benzoquinone-featured 5-lipoxygenase inhibitor RF-Id induces apoptotic death through downregulation of IAPs in human glioblastoma cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 167.	8.6	18
146	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1364-1375.	4.1	94
147	Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 811-830.	1.1	45
148	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1364-1375.	4.1	60
149	Role of perineural invasion as a prognostic factor in laryngeal cancer. <i>Oncology Letters</i> , 2016, 11, 2595-2598.	1.8	18
150	Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. <i>Oncology Letters</i> , 2016, 12, 2363-2370.	1.8	4
151	The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsons: from rash mitigation to the increase in anti-tumor activity. <i>Current Medical Research and Opinion</i> , 2016, 32, 1839-1848.	1.9	16
152	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1387-1401.	3.1	22
153	The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response. <i>Cell Death and Disease</i> , 2016, 7, e2299-e2299.	6.3	18
154	Pembrolizumab: the value of PDL1 biomarker in head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1075-1078.	3.1	13
155	Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. <i>Cancer Biology and Therapy</i> , 2016, 17, 1213-1220.	3.4	52
156	High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas. <i>Cancer Cell International</i> , 2016, 16, 59.	4.1	16
157	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
158	CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis. <i>Nanoscale</i> , 2016, 8, 7562-7571.	5.6	15
159	The cAMP analogs have potent anti-proliferative effects on medullary thyroid cancer cell lines. <i>Endocrine</i> , 2016, 51, 101-112.	2.3	16
160	Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. <i>Oncotarget</i> , 2016, 7, 85641-85649.	1.8	22
161	Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines. <i>Oncotarget</i> , 2016, 7, 4077-4092.	1.8	25
162	Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors. <i>Oncotarget</i> , 2016, 7, 20753-20772.	1.8	39

#	ARTICLE	IF	CITATIONS
163	Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 700-722.	1.6	12
164	Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment. <i>Current Drug Targets</i> , 2016, 18, 35-55.	2.1	16
165	Carcinogenetic mechanisms of endocrine disruptors in female cancers (Review). <i>Oncology Reports</i> , 2016, 36, 603-612.	2.6	34
166	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. <i>Medicine (United States)</i> , 2015, 94, e1861.	1.0	43
167	Levofolene modulates apoptosis induced by 5-fluorouracil through autophagy inhibition: Clinical and occupational implications. <i>International Journal of Oncology</i> , 2015, 46, 1893-1900.	3.3	14
168	Temporal bone meningioma involving the middle ear: A case report. <i>Oncology Letters</i> , 2015, 10, 2249-2252.	1.8	11
169	Atypical amplification of chromosome region 22q12 in melanoma: A case report. <i>Oncology Letters</i> , 2015, 10, 349-353.	1.8	0
170	Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients. <i>PLoS ONE</i> , 2015, 10, e0135331.	2.5	40
171	Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. <i>Oncotarget</i> , 2015, 6, 31461-31478.	1.8	40
172	The stress hormone norepinephrine increases migration of prostate cancer cells in vitro and in vivo. <i>International Journal of Oncology</i> , 2015, 47, 527-534.	3.3	71
173	Endocrine disruptors and female cancer: Informing the patients (Review). <i>Oncology Reports</i> , 2015, 34, 3-11.	2.6	22
174	PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy. <i>Endocrine</i> , 2015, 48, 363-370.	2.3	94
175	The methyl donor S-adenosylmethionine potentiates doxorubicin effects on apoptosis of hormone-dependent breast cancer cell lines. <i>Endocrine</i> , 2015, 50, 212-222.	2.3	19
176	A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate?. <i>Cancer Biology and Therapy</i> , 2015, 16, 1148-1159.	3.4	41
177	Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab. <i>Oncology Letters</i> , 2015, 9, 1327-1332.	1.8	5
178	New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 5789-5807.	6.4	51
179	Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells. <i>Cancer Biology and Therapy</i> , 2015, 16, 567-579.	3.4	50
180	Carbon nanotubes: Properties, biomedical applications, advantages and risks in patients and occupationally-exposed workers. <i>International Journal of Immunopathology and Pharmacology</i> , 2015, 28, 4-13.	2.1	59

#	ARTICLE	IF	CITATIONS
181	Gene interference strategies as a new tool for the treatment of prostate cancer. <i>Endocrine</i> , 2015, 49, 588-605.	2.3	27
182	MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e233.	5.1	122
183	EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 83.	8.6	20
184	Dicrocoelium dendriticum induces autophagic vacuoles accumulation in human hepatocarcinoma cells. <i>Veterinary Parasitology</i> , 2015, 212, 175-180.	1.8	6
185	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015, 11, 3091-3098.	2.4	17
186	HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer. <i>Histology and Histopathology</i> , 2015, 30, 707-14.	0.7	7
187	Polydatin administration improves serum biochemical parameters and oxidative stress markers during chronic alcoholism: a pilot study. <i>In Vivo</i> , 2015, 29, 405-8.	1.3	11
188	Silybin-Phosphatidylcholine Complex Protects Human Gastric and Liver Cells from Oxidative Stress. <i>In Vivo</i> , 2015, 29, 569-75.	1.3	18
189	Short-Term Diet and Moderate Exercise in Young Overweight Men Modulate Cardiocyte and Hepatocarcinoma Survival by Oxidative Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-7.	4.0	52
190	Serum Oxidative Stress Markers and Lipidomic Profile to Detect NASH Patients Responsive to an Antioxidant Treatment: A Pilot Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2014, 2014, 1-8.	4.0	66
191	Treatment of c-kit positive adenoid cystic carcinoma of the tongue: A case report. <i>Oncology Letters</i> , 2014, 8, 309-312.	1.8	5
192	Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: A comparative analysis through time lapse video-microscopy technique. <i>Cancer Biology and Therapy</i> , 2014, 15, 1524-1532.	3.4	14
193	Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro. <i>Cancer Biology and Therapy</i> , 2014, 15, 797-805.	3.4	40
194	High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antidepressant drugs as regulators of autophagy. <i>Cell Death and Disease</i> , 2014, 5, e1203-e1203.	6.3	108
195	From Protein Synthesis to Molecular Biology: The Appealing Tale of eIF-5A. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e199.	5.1	1
196	Keratin 5 expression in squamocellular carcinoma of the head and neck. <i>Oncology Letters</i> , 2014, 8, 2501-2504.	1.8	16
197	Transferrin-Conjugated SNALPs Encapsulating 2'-O-Methylated miR-34a for the Treatment of Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-7.	1.9	45
198	Urotensin receptor is overexpressed in colon cancer cell lines and in colon carcinoma in humans. <i>European Journal of Clinical Investigation</i> , 2014, 44, 285-294.	3.4	22

#	ARTICLE	IF	CITATIONS
199	Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients. <i>Journal of Immunotherapy</i> , 2014, 37, 26-35.	2.4	41
200	Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey. <i>Future Oncology</i> , 2014, 10, 69-78.	2.4	0
201	Pegylated liposomal doxorubicin in the management of ovarian cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 707-720.	3.4	45
202	Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 48.	8.6	24
203	Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor- $\hat{1}^3$ (PPAR- $\hat{1}^3$): At the cross-road of pancreatic cancer cell proliferation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 42-52.	7.4	36
204	Myrtucommulone production by a strain of <i>Neofusicoccum australe</i> endophytic in myrtle (<i>Myrtus</i>) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.6	23
205	Expression and localization of serine protease Htra1 in neuroblastoma: correlation with cellular differentiation grade. <i>Journal of Neuro-Oncology</i> , 2014, 117, 287-294.	2.9	13
206	Exploitation of viral properties for intracellular delivery. <i>Journal of Peptide Science</i> , 2014, 20, 468-478.	1.4	27
207	Advantages and risks of nanotechnologies in cancer patients and occupationally exposed workers. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1087-1101.	5.0	58
208	Zoledronic acid affects the cytotoxic effects of <i>Chlamydia pneumoniae</i> and the modulation of cytokine production in human osteosarcoma cells. <i>International Immunopharmacology</i> , 2014, 22, 66-72.	3.8	7
209	CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. <i>Cell Death and Disease</i> , 2014, 5, e1310-e1310.	6.3	70
210	Mir-34: A New Weapon Against Cancer?. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e195.	5.1	421
211	Vascular-homing peptides for targeted drug delivery and molecular imaging: Meeting the clinical challenges. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 1-12.	7.4	19
212	A mechanistic study on the cardiotoxicity of 5-fluorouracil in vitro and clinical and occupational perspectives. <i>Toxicology Letters</i> , 2014, 227, 151-156.	0.8	37
213	Erlotinib: early clinical development in brain cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1027-1037.	4.1	17
214	In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma. <i>PLoS ONE</i> , 2014, 9, e90005.	2.5	101
215	Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid. <i>Oncotarget</i> , 2014, 5, 10446-10459.	1.8	71
216	The Role of E-Cadherin Down-Regulation in Oral Cancer: CDH1 Gene Expression and Epigenetic Blockage. <i>Current Cancer Drug Targets</i> , 2014, 14, 115-127.	1.6	53

#	ARTICLE	IF	CITATIONS
217	Basal Cell Carcinoma: Molecular and Pathological Features. , 2014, , 75-88.		0
218	Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics. , 2014, , 29-57.		0
219	Tuberculous Lymphadenitis in Southern Italy: Clinical Aspects and Treatment Perspectives. Anti-Infective Agents, 2014, 12, 145-148.	0.4	0
220	eIF5A isoforms and cancer: two brothers for two functions?. Amino Acids, 2013, 44, 103-109.	2.7	92
221	Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation. Journal of Experimental and Clinical Cancer Research, 2013, 32, 24.	8.6	26
222	Interleukin-2 and Lanreotide in the Treatment of Medullary Thyroid Cancer: In Vitro and In Vivo Studies. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1567-E1574.	3.6	14
223	Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC. Expert Opinion on Drug Safety, 2013, 12, 729-740.	2.4	15
224	Structural and functional alterations of cellular components as revealed by electron microscopy. Microscopy Research and Technique, 2013, 76, 1057-1069.	2.2	17
225	miRâ€29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myelomaâ€related bone disease. Journal of Cellular Physiology, 2013, 228, 1506-1515.	4.1	156
226	Hydrogen sulfide reduces cell adhesion and relevant inflammatory triggering by preventing ADAM17â€dependent TNFâ€ α activation. Journal of Cellular Biochemistry, 2013, 114, 1536-1548.	2.6	38
227	Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco-2 cell. Journal of Translational Medicine, 2013, 11, 264.	4.4	77
228	Î³-Tocopherol inhibits human prostate cancer cell proliferation by up-regulation of transglutaminase 2 and down-regulation of cyclins. Amino Acids, 2013, 44, 45-51.	2.7	21
229	Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. Expert Review of Anticancer Therapy, 2013, 13, 407-420.	2.4	22
230	Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?. Expert Opinion on Biological Therapy, 2013, 13, 149-151.	3.1	16
231	EGFR mutational status in penile cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 501-505.	3.4	14
232	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opinion on Biological Therapy, 2013, 13, 241-255.	3.1	50
233	Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 761-765.	1.6	16
234	Interleukin 18: Friend or foe in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 296-303.	7.4	47

#	ARTICLE	IF	CITATIONS
235	1320 ZOLEDRONIC ACID (ZOL) ENCAPSULATED INTO LIPOSOMES AND NANOPARTICLES: ENHANCED ANTITUMOR ACTIVITY IN 3D- PROSTATE CARCINOMA SPHEROIDS. <i>Journal of Urology</i> , 2013, 189, .	0.4	0
236	Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials. <i>European Journal of Cancer</i> , 2013, 49, 593-603.	2.8	106
237	Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 51-66.	3.1	13
238	Emerging pathways as individualized therapeutic target of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, S95-S109.	3.1	37
239	Stealth Liposomes Encapsulating Zoledronic Acid: A New Opportunity To Treat Neuropathic Pain. <i>Molecular Pharmaceutics</i> , 2013, 10, 1111-1118.	4.6	22
240	Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. <i>Journal of Cellular Physiology</i> , 2013, 228, 130-141.	4.1	15
241	Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment. <i>Cancer Biology and Therapy</i> , 2013, 14, 467-468.	3.4	5
242	DTNQ-Pro, a Mimetic Dipeptide, Sensitizes Human Colon Cancer Cells to 5-Fluorouracil Treatment. <i>Journal of Amino Acids</i> , 2013, 2013, 1-7.	5.8	8
243	Nanotechnologies in Cancer. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-3.	2.5	3
244	Bisphosphonates and Cancer: What Opportunities from Nanotechnology?. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-17.	2.5	24
245	Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-10.	2.5	62
246	Urotensin-II Ligands: An Overview from Peptide to Nonpeptide Structures. <i>Journal of Amino Acids</i> , 2013, 2013, 1-15.	5.8	13
247	Comment on: EGFR mutational status in Brazilian patients with penile carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 857-859.	3.4	2
248	Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. <i>Cell Death and Disease</i> , 2013, 4, e641-e641.	6.3	57
249	Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. <i>Cell Death and Disease</i> , 2013, 4, e878-e878.	6.3	50
250	BAG3 Is a Novel Serum Biomarker for Pancreatic Adenocarcinomas. <i>American Journal of Gastroenterology</i> , 2013, 108, 1178-1180.	0.4	30
251	Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients. <i>Cancer Biology and Therapy</i> , 2013, 14, 469-475.	3.4	82
252	Synergistic cytotoxic effects of inorganic phosphate and chemotherapeutic drugs on human osteosarcoma cells. <i>Oncology Reports</i> , 2013, 29, 1689-1696.	2.6	14

#	ARTICLE	IF	CITATIONS
253	Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties. Protein and Peptide Letters, 2013, 20, 412-423.	0.9	6
254	Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. Molecular and Clinical Oncology, 2013, 1, 726-732.	1.0	2
255	Type I Interferons: Ancient Peptides with Still Under-Discovered Anti-Cancer Properties. Protein and Peptide Letters, 2013, 20, 412-423.	0.9	12
256	Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models. PLoS ONE, 2013, 8, e62657.	2.5	20
257	The Synergistic Effect of Everolimus and Chloroquine on Endothelial Cell Number Reduction Is Paralleled by Increased Apoptosis and Reduced Autophagy Occurrence. PLoS ONE, 2013, 8, e79658.	2.5	24
258	Combined Treatment with PPAR- γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?. Current Cancer Drug Targets, 2013, 13, 460-471.	1.6	19
259	Neuroendocrine Differentiation in Prostate Cancer. , 2013, , 87-109.		0
260	Type I interferons: ancient peptides with still under-discovered anti-cancer properties. Protein and Peptide Letters, 2013, 20, 412-23.	0.9	10
261	Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms. Oncology Reports, 2012, 27, 409-15.	2.6	17
262	Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: <i>In Vitro</i> and <i>In Vivo</i> Evidence. Clinical Cancer Research, 2012, 18, 6260-6270.	7.0	213
263	Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biology and Therapy, 2012, 13, 1491-1500.	3.4	57
264	Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier. Current Cancer Drug Targets, 2012, 12, 186-196.	1.6	43
265	Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier. Current Drug Metabolism, 2012, 13, 61-69.	1.2	56
266	Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2012, 12, 1283-1288.	2.4	8
267	pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma. Cancer Biology and Therapy, 2012, 13, 967-977.	3.4	41
268	miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death and Disease, 2012, 3, e436-e436.	6.3	137
269	Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells. Cell Death and Disease, 2012, 3, e276-e276.	6.3	36
270	BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death and Disease, 2012, 3, e259-e259.	6.3	74

#	ARTICLE	IF	CITATIONS
271	Role of systemic chemotherapy in the management of resected or resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. <i>Oncology Reports</i> , 2012, 27, 1849-56.	2.6	55
272	Editorial [Hot Topic: Nanotechnological and Biotechnological Strategies for Drug Delivery (Guest) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.2	2
273	Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2012, 12, 814-822.	1.6	45
274	Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here. <i>Current Drug Metabolism</i> , 2012, 13, 4-21.	1.2	20
275	Immune-modulating Effects of the Newest Cetuximab-based Chemoimmunotherapy Regimen in Advanced Colorectal Cancer Patients. <i>Journal of Immunotherapy</i> , 2012, 35, 440-447.	2.4	34
276	Breast MALT lymphomas: A clinicopathological and cytogenetic study of 9 cases. <i>Oncology Reports</i> , 2012, 28, 1211-1216.	2.6	9
277	Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. <i>British Journal of Cancer</i> , 2012, 106, 1648-1659.	6.4	38
278	Effects of statins and farnesyl transferase inhibitors on <scp>ERK</scp> phosphorylation, apoptosis and cell viability in nonâ€small lung cancer cells. <i>Cell Proliferation</i> , 2012, 45, 557-565.	5.3	65
279	Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 637-646.	3.3	38
280	Everolimus is an active agent in medullary thyroid cancer: a clinical and <i>in vitro</i> study. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 1563-1572.	3.6	42
281	Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 603-609.	2.3	34
282	5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 60.	8.6	95
283	Molecular Targets for the Treatment of Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2012, 12, 757-767.	1.6	59
284	New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. <i>Biotechnology Advances</i> , 2012, 30, 302-309.	11.7	84
285	The PPAR-Î³ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-Î² treated pancreatic cancer cells. <i>Biotechnology Advances</i> , 2012, 30, 169-184.	11.7	76
286	Role of endothelial nitric oxide synthase (eNOS) in chronic stressâ€promoted tumour growth. <i>Journal of Cellular and Molecular Medicine</i> , 2012, 16, 920-926.	3.6	43
287	Cetuximab Â± chemotherapy enhances dendritic cellâ€mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigenâ€specific cytotoxic Tâ€cell response <i>in vitro</i>. <i>International Journal of Cancer</i> , 2012, 130, 1577-1589.	5.1	67
288	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. <i>Oncotarget</i> , 2012, 3, 1246-1258.	1.8	138

#	ARTICLE	IF	CITATIONS
289	Abstract 891: The chemokine receptor CXCR7 transduces its signal through mTOR: the role of everolimus. , 2012, , .		0
290	Abstract 5231:Zoledronic acid encapsulated into liposomes and nanoparticles: Enhanced antitumor activity in 3D-prostate carcinoma spheroids. , 2012, , .		0
291	Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?. Expert Opinion on Investigational Drugs, 2011, 20, 881-895.	4.1	13
292	The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?. Expert Review of Anticancer Therapy, 2011, 11, 139-142.	2.4	11
293	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death and Disease, 2011, 2, e152-e152.	6.3	191
294	Analysis of interaction partners for eukaryotic translation elongation factor 1A M-domain by functional proteomics. Biochimie, 2011, 93, 1738-1746.	2.6	15
295	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. Oncology Reports, 2011, 25, 1545-8.	2.6	4
296	Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 955-964.	3.3	98
297	A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma. Journal of Neuro-Oncology, 2011, 102, 417-424.	2.9	60
298	Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. Journal of Translational Medicine, 2011, 9, 171.	4.4	192
299	HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. Journal of Cellular Physiology, 2011, 226, 2378-2390.	4.1	139
300	Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. Journal of Cellular Biochemistry, 2011, 112, 341-353.	2.6	29
301	Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. International Journal of Pharmaceutics, 2011, 403, 292-297.	5.2	79
302	Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC). Current Cancer Drug Targets, 2011, 11, 123-129.	1.6	42
303	Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death and Disease, 2011, 2, e150-e150.	6.3	81
304	Epigenetic fingerprint in endometrial carcinogenesis: The hypothesis of a uterine field cancerization. Cancer Biology and Therapy, 2011, 12, 447-457.	3.4	37
305	Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biology and Therapy, 2011, 12, 112-118.	3.4	37
306	GPR30 is overexpressed in post-puberal testicular germ cell tumors. Cancer Biology and Therapy, 2011, 11, 609-613.	3.4	65

#	ARTICLE	IF	CITATIONS
307	Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: A DMET microarray profiling study. <i>Cancer Biology and Therapy</i> , 2011, 12, 780-787.	3.4	79
308	The role of tissue microarray in the era of target-based agents. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 859-869.	2.4	25
309	Nanotechnologies to use zoledronic acid as a potent antitumoral agent. <i>Journal of Drug Delivery Science and Technology</i> , 2011, 21, 283-284.	3.0	2
310	Predicting Efficacy and Toxicity in the Era of Targeted Therapy: Focus on Anti-EGFR and Anti-VEGF Molecules. <i>Current Drug Metabolism</i> , 2011, 12, 944-955.	1.2	15
311	Nanotechnologies: New Opportunities for Old Drugs. The Case of Aminobisphosphonates. <i>Journal of Nanomedicine & Biotherapeutic Discovery</i> , 2011, 01, .	0.6	12
312	Abstract 2609: Tissue transglutaminase (TG2) promotes resistance to HDAC inhibitor (HDI) vorinostat in cancer cells. , 2011, , .		0
313	Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 1137-1143.	2.3	26
314	Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 837-844.	2.3	73
315	β -Glutamyl 16-diaminopropane derivative of vasoactive intestinal peptide: a potent anti-oxidative agent for human epidermoid cancer cells. <i>Amino Acids</i> , 2010, 39, 661-670.	2.7	4
316	In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 Td (oxide)-pol of Controlled Release, 2010, 148, 255-263.	9.9	56
317	SCREENING FOR HYPOTHYROIDISM IN OLDER HOSPITALIZED PATIENTS WITH ANEMIA: A NEW INSIGHT INTO AN OLD DISEASE. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1825-1827.	2.6	19
318	Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. <i>European Journal of Cancer Care</i> , 2010, 19, 200-204.	1.5	9
319	Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib. <i>Oncologist</i> , 2010, 15, 85-92.	3.7	162
320	The Serine Protease HtrA1 Specifically Interacts and Degrades the Tuberous Sclerosis Complex 2 Protein. <i>Molecular Cancer Research</i> , 2010, 8, 1248-1260.	3.4	41
321	High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. <i>Annals of Oncology</i> , 2010, 21, 1565.	1.2	38
322	Panitumumab: a new frontier of target therapy for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 499-505.	2.4	20
323	Latest developments in targeted therapy for hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1635-1646.	2.4	8
324	Metronomic administration of Zoledronic Acid and Taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. <i>Cancer Biology and Therapy</i> , 2010, 10, 543-548.	3.4	44

#	ARTICLE	IF	CITATIONS
325	Circadian rhythms, adrenergic hormones and trafficking of hematopoietic stem cells. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 567-575.	3.4	18
326	Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. <i>Cancer Biology and Therapy</i> , 2010, 9, 423-429.	3.4	30
327	Randomized Phase III Trial on Gemcitabine Versus Mytomicin in Recurrent Superficial Bladder Cancer: Evaluation of Efficacy and Tolerance. <i>Journal of Clinical Oncology</i> , 2010, 28, 543-548.	1.6	142
328	Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab in advanced non-small-cell-lung cancer patients. <i>Cancer Biology and Therapy</i> , 2010, 9, 685-693.	3.4	34
329	Low-Dose Metronomic Oral Administration of Vinorelbine in the First-line Treatment of Elderly Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2010, 10, 301-306.	2.4	84
330	Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). <i>European Journal of Cancer</i> , 2010, 46, 1703-1711.	2.8	58
331	Zoledronic acid: an unending tale for an antiresorptive agent. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 141-154.	1.8	50
332	Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin. <i>Oncology Reports</i> , 2010, 23, 171-5.	2.6	34
333	Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1095-1108.	1.8	10
334	Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. <i>Cancer Biology and Therapy</i> , 2009, 8, 648-653.	3.4	88
335	Target-based agents in neo-adjuvant treatment of liver metastases from colo-rectal cancer: Secret weapons in anticancer war?. <i>Cancer Biology and Therapy</i> , 2009, 8, 1709-1718.	3.4	3
336	Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. <i>Cancer Biology and Therapy</i> , 2009, 8, 1183-1190.	3.4	51
337	MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients. <i>Cancer Biology and Therapy</i> , 2009, 8, 996-999.	3.4	8
338	Pyk2 and Cyr61 at the cross-road of cAMP-dependent signalling in invasiveness and neuroendocrine differentiation of prostate cancer. <i>Cancer Biology and Therapy</i> , 2009, 8, 243-244.	3.4	2
339	Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy. <i>Current Cancer Drug Targets</i> , 2009, 9, 854-870.	1.6	20
340	Editorial [Hot topic: Target Therapy of Bone Metastases and Tumours (Guest Editors: M. Caraglia and Tj ETQq0 0 0 rgBT /Overlock 10 T	1.6	0
341	Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine. <i>Cancer Biology and Therapy</i> , 2009, 8, 497-502.	3.4	19
342	Denosumab: The Era of Targeted Therapies in Bone Metastatic Diseases. <i>Current Cancer Drug Targets</i> , 2009, 9, 834-842.	1.6	14

#	ARTICLE	IF	CITATIONS
343	Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects. <i>Current Cancer Drug Targets</i> , 2009, 9, 791-800.	1.6	33
344	Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. <i>International Journal of Cancer</i> , 2009, 125, 2004-2013.	5.1	31
345	W7FW14F apomyoglobin amyloid aggregates-mediated apoptosis is due to oxidative stress and AKT inactivation caused by Ras and Rac. <i>Journal of Cellular Physiology</i> , 2009, 221, 412-423.	4.1	23
346	Possible antioxidant role of SPA therapy with chlorine-sulphur-bicarbonate mineral water. <i>Amino Acids</i> , 2009, 36, 161-165.	2.7	29
347	Potential role of type I interferons in the treatment of pituitary adenomas. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2009, 10, 125-133.	5.7	14
348	Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 863-866.	2.3	9
349	Protein kinase A as a biological target in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 83-92.	3.4	75
350	High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 39.	8.6	6
351	Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 7.	8.6	8
352	Two faces for Janus: recombinant human erythropoiesis-stimulating agents and cancer mortality. <i>Expert Review of Hematology</i> , 2009, 2, 513-515.	2.2	6
353	New treatment approaches in renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2009, 20, 893-900.	1.4	35
354	Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways. <i>Current Cancer Drug Targets</i> , 2009, 9, 690-704.	1.6	44
355	Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women ≥ 65 years of age. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 285-292.	2.3	39
356	Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. <i>Journal of Molecular Medicine</i> , 2008, 86, 1341-1351.	3.9	30
357	Impairment of the metastatic activity of melanoma cells by transglutaminase-catalyzed incorporation of polyamines into laminin and Matrigel. <i>Amino Acids</i> , 2008, 34, 251-256.	2.7	14
358	Experimental study on vasoactive intestinal peptide (VIP) and its diaminopropane bound (VIP-DAP) analog in solution. <i>Amino Acids</i> , 2008, 35, 275-281.	2.7	3
359	Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. <i>Supportive Care in Cancer</i> , 2008, 16, 209-214.	2.2	18
360	Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. <i>Cancer</i> , 2008, 113, 2524-2531.	4.1	88

#	ARTICLE	IF	CITATIONS
361	The Multidrug Transporter P-Glycoprotein: A Mediator of Melanoma Invasion?. <i>Journal of Investigative Dermatology</i> , 2008, 128, 957-971.	0.7	91
362	<i>In vivo</i> anti- α -myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. <i>British Journal of Haematology</i> , 2008, 143, 520-531.	2.5	59
363	Bovine serum amine oxidase and spm potentiate docetaxel and interferon- γ effects in inducing apoptosis on human cancer cells through the generation of oxidative stress. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2008, 1783, 2269-2278.	4.1	11
364	Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 86-90.	2.2	2
365	Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 79-85.	2.2	7
366	The N-terminal 1-16 peptide derived in vivo from protein seminal vesicle protein IV modulates α -thrombin activity: potential clinical implications. <i>Experimental and Molecular Medicine</i> , 2008, 40, 541.	7.7	0
367	A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology. <i>Annals of Oncology</i> , 2007, 18, 960-961.	1.2	2
368	Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan. <i>Annals of Oncology</i> , 2007, 18, 1579-1580.	1.2	1
369	Adenylate Cyclase/cAMP Pathway Downmodulation Counteracts Apoptosis Induced by IFN- γ in Human Epidermoid Cancer Cells. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 129-136.	1.2	13
370	A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss. <i>Annals of Oncology</i> , 2007, 18, 201-202.	1.2	7
371	Phase II studies of anticancer chemotherapy: indirect evidence of poor quality. <i>Annals of Oncology</i> , 2007, 18, 403.	1.2	2
372	Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 4482-4486.	7.0	163
373	Role of the FAD-dependent polyamine oxidase in the selective formation of N1,N8-bis(1 β -Tj ETQq1 1 0.784314 rgBTJ /Overlock 10 Tf 5	3.4	5
374	Concomitant Occurrence of Facial Cutaneous and Parotid Gland Metastases from Rectal Cancer after Preoperative Chemoradiotherapy. <i>Oncology Research and Treatment</i> , 2007, 30, 324-326.	1.2	3
375	Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors. <i>Oncology Reports</i> , 2007, , .	2.6	8
376	Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours. <i>Current Signal Transduction Therapy</i> , 2007, 2, 165-173.	0.5	0
377	Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. <i>Anti-Cancer Drugs</i> , 2007, 18, 781-791.	1.4	15
378	Atypical Cutaneous Lymphoid Hyperplasia Induced by Chemotherapy in a Patient with Advanced Colon Carcinoma. <i>Clinical Colorectal Cancer</i> , 2007, 6, 728-730.	2.3	4

#	ARTICLE	IF	CITATIONS
379	The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro-apoptotic activity of interferon- γ through the inhibition of multiple survival pathways. <i>International Journal of Cancer</i> , 2007, 121, 2317-2330.	5.1	21
380	R115777 (Zarnestra®)/Zoledronic acid (Zometa®) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. <i>Journal of Cellular Physiology</i> , 2007, 211, 533-543.	4.1	57
381	C-Raf antagonizes apoptosis induced by IFN- γ in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. <i>Cell Death and Differentiation</i> , 2007, 14, 952-962.	11.2	48
382	Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. <i>BMC Cancer</i> , 2007, 7, 18.	2.6	72
383	Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1095-1106.	4.1	133
384	Change in TNF- α Receptor Expression Is a Relevant Event in Doxorubicin-Induced H9c2 Cardiomyocyte Cell Death. <i>Journal of Interferon and Cytokine Research</i> , 2007, 27, 589-598.	1.2	38
385	Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract. <i>Amino Acids</i> , 2007, 32, 395-400.	2.7	9
386	Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products. <i>Amino Acids</i> , 2007, 33, 273-281.	2.7	6
387	Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2007, 2, 119-134.	1.6	51
388	Cetuximab is an active treatment of metastatic and chemorefractory thymoma. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 757.	3.0	70
389	Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 383-396.	1.6	28
390	Effects of VIP and VIP-DAP on Proliferation and Lipid Peroxidation Metabolism in Human KB Cells. <i>Annals of the New York Academy of Sciences</i> , 2006, 1070, 167-172.	3.8	3
391	Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 34-39.	2.3	66
392	Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. <i>BMC Cancer</i> , 2006, 6, 125.	2.6	32
393	Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 98-108.	2.6	33
394	Molecular dynamics simulation and automated docking of the pro-apoptotic bax protein and its complex with a peptide designed from the Bax-binding domain of anti-apoptotic Ku70. <i>Journal of Cellular Biochemistry</i> , 2006, 99, 305-318.	2.6	28
395	Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN- γ in Head and Neck Cancer Cells In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 617-625.	7.0	88
396	Emerging anti-cancer molecular mechanisms of aminobisphosphonates. <i>Endocrine-Related Cancer</i> , 2006, 13, 7-26.	3.1	123

#	ARTICLE	IF	CITATIONS
397	Targeting Raf-kinase: molecular rationales and translational issues. <i>Annals of Oncology</i> , 2006, 17, vii124-vii127.	1.2	27
398	Mechanisms of Disease: preclinical reports of antineoplastic synergistic action of bisphosphonates. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 325-338.	4.3	64
399	EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2006, 1, 209-222.	1.6	8
400	Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. <i>Oncology Reports</i> , 2006, 15, 1351-7.	2.6	40
401	Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors. <i>Current Opinion in Oncology</i> , 2005, 17, 212-217.	2.4	41
402	Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. <i>British Journal of Cancer</i> , 2005, 92, 1621-1625.	6.4	46
403	Alpha-interferon and its effects on signal transduction pathways. <i>Journal of Cellular Physiology</i> , 2005, 202, 323-335.	4.1	113
404	Mitogen-activated protein kinases and asthma. <i>Journal of Cellular Physiology</i> , 2005, 202, 642-653.	4.1	92
405	Electromagnetic fields at mobile phone frequency induce apoptosis and inactivation of the multi-chaperone complex in human epidermoid cancer cells. <i>Journal of Cellular Physiology</i> , 2005, 204, 539-548.	4.1	95
406	New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancer. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 1-10.	4.2	81
407	Atrial fibrillation following chemotherapy for stage III diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease). <i>Annals of Hematology</i> , 2005, 84, 192-193.	1.8	18
408	Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 563-568.	2.3	29
409	Mediastinal Images Resembling Thymus Following 131-I Treatment for Thyroid Cancer. <i>Monaldi Archives for Chest Disease</i> , 2005, 63, 114-7.	0.6	5
410	Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro. <i>Journal of Immunology</i> , 2005, 175, 820-828.	0.8	69
411	Conditions Suggesting Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 3844-3846.	1.6	12
412	Alternative therapy of earth elements increases the chondroprotective effects of chondroitin sulfate in mice. <i>Experimental and Molecular Medicine</i> , 2005, 37, 476-481.	7.7	31
413	A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications. <i>Annals of Oncology</i> , 2005, 16, 1980-1981.	1.2	2
414	Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation. <i>Cancer Biology and Therapy</i> , 2005, 4, 1159-1167.	3.4	20

#	ARTICLE	IF	CITATIONS
415	Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia. <i>Cancer Biology and Therapy</i> , 2005, 4, 39-45.	3.4	38
416	Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications. <i>Current Drug Targets</i> , 2005, 6, 301-323.	2.1	56
417	Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways. <i>Current Drug Targets</i> , 2005, 6, 289-300.	2.1	15
418	Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase. <i>Current Drug Targets</i> , 2005, 6, 337-351.	2.1	33
419	Glucocorticoids induce G1 Arrest of Lymphoblastic Cells through Retinoblastoma Protein Rb1 Dephosphorylation in Childhood Acute Lymphoblastic Leukemia In Vivo. <i>Cancer Biology and Therapy</i> , 2004, 3, 470-476.	3.4	11
420	Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin. <i>Experimental and Molecular Medicine</i> , 2004, 36, 268-273.	7.7	16
421	The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate. <i>Oncogene</i> , 2004, 23, 6900-6913.	5.9	73
422	A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. <i>British Journal of Cancer</i> , 2004, 90, 1710-1714.	6.4	31
423	Protein-polyamine conjugation by transglutaminase in cancer cell differentiation: Review article. <i>Amino Acids</i> , 2004, 26, 331-7.	2.7	32
424	Translational and post-translational modifications of proteins as a new mechanism of action of Alpha-Interferon: Review article. <i>Amino Acids</i> , 2004, 26, 409-17.	2.7	17
425	Acetylation of proteins as novel target for antitumor therapy: Review article. <i>Amino Acids</i> , 2004, 26, 435-41.	2.7	77
426	The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: Review article. <i>Amino Acids</i> , 2004, 26, 443-8.	2.7	132
427	Non-thermal effects of electromagnetic fields at mobile phone frequency on the refolding of an intracellular protein: Myoglobin. <i>Journal of Cellular Biochemistry</i> , 2004, 93, 188-196.	2.6	48
428	Apoptosis induced by interferon- γ and antagonized by EGF is regulated by caspase-3-mediated cleavage of gelsolin in human epidermoid cancer cells. <i>Journal of Cellular Physiology</i> , 2004, 201, 71-83.	4.1	37
429	The role of somatostatin receptors in the medical treatment of acromegaly. <i>Digestive and Liver Disease</i> , 2004, 36, S55-S59.	0.9	8
430	Alpha-Interferon and Its Effects on Signalling Pathways Within Cells. <i>Current Protein and Peptide Science</i> , 2004, 5, 475-485.	1.4	48
431	Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (Iressa?), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. <i>Journal of Cellular Physiology</i> , 2003, 195, 139-150.	4.1	127
432	Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. <i>British Journal of Cancer</i> , 2003, 88, 1971-1978.	6.4	138

#	ARTICLE	IF	CITATIONS
433	EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon- β -mediated apoptosis in epidermoid cancer cells. <i>Cell Death and Differentiation</i> , 2003, 10, 218-229.	11.2	67
434	An Ubiquitin Ligase Recognizing a Protein Oxidized by Iron: Implications for the Turnover of Oxidatively Damaged Proteins. <i>Journal of Biochemistry</i> , 2003, 134, 175-182.	1.7	28
435	The Eukaryotic Initiation Factor 5A Is Involved in the Regulation of Proliferation and Apoptosis Induced by Interferon- α and EGF in Human Cancer Cells. <i>Journal of Biochemistry</i> , 2003, 133, 757-765.	1.7	65
436	Ubiquitination of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells. <i>Biochemical Journal</i> , 2003, 370, 205-212.	3.7	26
437	Theophylline-induced Apoptosis is Paralleled by Protein Kinase A-dependent Tissue Transglutaminase Activation in Cancer Cells. <i>Journal of Biochemistry</i> , 2002, 132, 45-52.	1.7	19
438	Percutaneous Ethanol Injection Efficacy in the Treatment of Large Symptomatic Thyroid Cystic Nodules: Ten-Year Follow-Up of a Large Series. <i>Thyroid</i> , 2002, 12, 815-821.	4.5	122
439	Comparison of Two Provocative Tests for Calcitonin in Medullary Thyroid Carcinoma: Omeprazole vs Pentagastrin. <i>Clinical Chemistry</i> , 2002, 48, 1505-1510.	3.2	38
440	Percutaneous Ethanol Injection of Autonomous Thyroid Nodules With a Volume Larger than 40ml: Three Years of Follow-up. <i>Clinical Radiology</i> , 2001, 56, 895-901.	1.1	34
441	Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. <i>British Journal of Cancer</i> , 2001, 84, 1586-1590.	6.4	104
442	The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. <i>Amino Acids</i> , 2001, 20, 91-104.	2.7	66
443	Current approaches and perspectives in the therapy of medullary thyroid carcinoma. <i>Cancer</i> , 2001, 91, 1797-1808.	4.1	111
444	Homology modelling of the human eukaryotic initiation factor 5A (eIF-5A). <i>Protein Engineering, Design and Selection</i> , 2001, 14, 881-890.	2.1	44
445	Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice. <i>Melanoma Research</i> , 2000, 10, 435-443.	1.2	21
446	Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. <i>FEBS Journal</i> , 2000, 267, 3919-3936.	0.2	62
447	Slow Release Lanreotide in Combination with Interferon- β in the Treatment of Symptomatic Advanced Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 983-988.	3.6	70
448	Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by a computer-assisted image analysis. <i>European Journal of Cancer</i> , 2000, 36, 1572-1577.	2.8	24
449	Slow Release Lanreotide in Combination with Interferon- β in the Treatment of Symptomatic Advanced Medullary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 983-988.	3.6	54
450	Post-Translational Modifications of Eukaryotic Initiation Factor-5A (eIF-5a) as a New Target for Anti-Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 1999, 472, 187-198.	1.6	33

#	ARTICLE	IF	CITATIONS
451	Interferon- β induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. <i>Cell Death and Differentiation</i> , 1999, 6, 773-780.	11.2	79
452	8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor. <i>British Journal of Cancer</i> , 1999, 81, 1134-1141.	6.4	16
453	Structural organization of the human eukaryotic initiation factor 5A precursor and its site-directed variant Lys50 ? <i>Arg. Amino Acids</i> , 1999, 16, 91-106.	2.7	3
454	Familial papillary thyroid microcarcinoma: a new clinical entity. <i>Lancet, The</i> , 1999, 353, 637-639.	13.7	184
455	Up-regulated EGF receptors undergo to rapid internalization and ubiquitin-dependent degradation in human cancer cells exposed to 8-Cl-cAMP. <i>FEBS Letters</i> , 1999, 447, 203-208.	2.8	4
456	Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications. <i>Cancer Immunology, Immunotherapy</i> , 1998, 46, 121-127.	4.2	2
457	Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. <i>British Journal of Haematology</i> , 1998, 102, 746-752.	2.5	99
458	Tissue transglutaminase expression affects hypusine metabolism in BALB/c 3T3 cells. <i>FEBS Letters</i> , 1998, 437, 34-38.	2.8	19
459	Daily Low-Dose Subcutaneous Recombinant Interleukin-2 by Alternate Weekly Administration. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 48-53.	1.3	23
460	Interferon β 2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. <i>Biochemical Journal</i> , 1997, 324, 737-741.	3.7	44
461	Extracellular adenosine 5 α €² triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation. <i>Immunology Letters</i> , 1997, 55, 69-78.	2.5	21
462	High-dose recombinant interleukin-2/verapamil combination in advanced cancer. <i>European Journal of Cancer</i> , 1996, 32, 1436-1437.	2.8	4
463	Bryostatins enhance lymphokine activated killer sensitivity and modulates the β 1 integrin profile of cultured human tumor cells. <i>Anti-Cancer Drugs</i> , 1995, 6, 285-290.	1.4	10
464	β -interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. <i>International Journal of Cancer</i> , 1995, 61, 342-347.	5.1	36
465	Cytosine arabinoside (Ara-C) plus alpha-interferon (α IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens. <i>British Journal of Haematology</i> , 1994, 88, 421-423.	2.5	10
466	β -Interferon Induces Depletion of Intracellular Iron Content and Up Regulation of Functional Transferrin Receptors on Human Epidermoid Cancer kb Cells. <i>Biochemical and Biophysical Research Communications</i> , 1994, 203, 281-288.	2.1	9
467	Interleukin 1 β -511T gene (IL1 β) polymorphism is correlated with gastric cancer in the Caucasian population: Results from a meta-analysis. <i>Oncology Reports</i> , 1994, 20, 1213.	2.6	12
468	Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: A single center experience. <i>Oncology Reports</i> , 1994, 20, 385.	2.6	7

#	ARTICLE	IF	CITATIONS
469	Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy. <i>Anti-Cancer Drugs</i> , 1994, 5, 379-393.	1.4	18
470	Cytosine arabinoside increases the binding of ¹²⁵ I-labelled epidermal growth factor and ¹²⁵ I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth) Tj ETQq0 0 0 rgB4.0 Overlockd 10 Tf 50 6	4.0	10
471	Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer-and lymphokine-activated-killer-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 1992, 34, 272-278.	4.2	8
472	Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. <i>Oncology Reports</i> , 0, , .	2.6	2
473	Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients. <i>Oncology Reports</i> , 0, , .	2.6	1